Pharmaceutical Innovations, Collaborative Research Initiatives, and Increased Awareness Driving Clostridium Difficile Infection Treatment Market GrowthRockville, MD, Jan. 23, 2025 (GLOBE NEWSWIRE) -- ...

Medically reviewed by Lindsey Waldman, MD, RD A C. diff (Clostridioides difficile ) diet may help alleviate diarrhea (the ...

It’s estimated that about 25% of people (or one in four) who have a C. diff infection will experience a repeat infection.

Help us make Medscape the best clinical resource possible. Please use this form to submit your questions or comments on how to make this resource center more useful to clinicians.

Thank you for taking time to provide your feedback to the editors. Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.

Pfizer's vaccine for Clostridium difficile (C. US biotech Vedanta Biosciences has been awarded up to $76.9 million to develop VE303 for high-risk Clostridioides difficile (C. diff.) infection by ...

C.diff infection rates and how frequently the hospital appropriately addresses sepsis and septic shock. The Republic also included for these hospitals the cost of hip and knee replacement ...

Patients suffering from a recurrent infection with the C difficile bacteria have benefited from a microbiome treatment from Rebiotix. The results from the open label phase 2 trial confirm that ...

diff infection (CDI) instead of aiming to reduce the risk and prevention of disease. Pfizer estimates ~500k infections annually in the U.S., and no vaccine options currently available ...

NICE have found that the evidence supporting FMT for recurrent Clostridium difficile infection is sufficient for the procedure to be carried out. However, it is only considered when patients have ...